Table 2.
Summary of the demographics of the patients treated with CRS according to the KRAS/BRAF status
| Variable | wtBRAF (n = 100) | mutBRAF (n = 42) | P | wtKRAS (n = 74) | mutKRAS (n = 68) | P |
|---|---|---|---|---|---|---|
| Age (years) | 0.190 | 0.106 | ||||
| ≥60 | 38 (38.0) | 21 (50.0) | 26 (35.1) | 33 (48.5) | ||
| <60 | 62 (62.0) | 21 (50.0) | 48 (64.9) | 35 (51.5) | ||
| Sex | 0.200 | 0.639 | ||||
| Male | 57 (57.0) | 19 (45.2) | 41 (55.4) | 35 (51.5) | ||
| Female | 43 (43.0) | 23 (54.8) | 33 (44.6) | 33 (48.5) | ||
| T category | 0.002 | 0.768 | ||||
| T0–3 | 54 (54.0) | 11 (26.2) | 33 (44.6) | 32 (47.1) | ||
| T4 | 46 (46.0) | 31 (73.8) | 41 (55.4) | 36 (52.9) | ||
| N category | 0.680 | 0.653 | ||||
| N0 | 17 (17.0) | 6 (14.3) | 11 (14.9) | 12 (17.6) | ||
| N1–2 | 83 (83.0) | 36 (85.7) | 63 (85.1) | 56 (82.4) | ||
| CRS | 0.180 | 0.819 | ||||
| CC-0/1 | 43 (43.0) | 12 (28.5) | 28 (37.9) | 27 (39.7) | ||
| CC-2 | 57 (57.0) | 30 (71.5) | 46 (62.1) | 41 (60.3) | ||
| HIPEC | 0.030 | 0.695 | ||||
| Yes | 50 (50.0) | 13 (31.0) | 36 (48.6) | 27 (39.7) | ||
| No | 50 (50.0) | 29 (69.0) | 38 (51.4) | 41 (60.3) | ||
| Perioperative chemotherapy | 0.240 | 0.452 | ||||
| Yes | 72 (72.0) | 26 (62.0) | 49 (66.2) | 49 (72.1) | ||
| No | 28 (28.0) | 16 (38.0) | 25 (33.8) | 19 (27.9) | ||
| Preventive stoma | 0.820 | 0.682 | ||||
| Yes | 29 (29.0) | 13 (31.0) | 23 (31.1) | 19 (27.9) | ||
| No | 71 (71.0) | 29 (69.0) | 51 (68.9) | 49 (72.1) | ||
| Location of tumor | 0.060 | 0.320 | ||||
| Right-sided colon | 43 (71.0) | 26 (62.0) | 33 (44.6) | 36 (52.9) | ||
| Left-sided colon | 43 (43.0) | 11 (26.2) | 30 (40.5) | 24 (35.3) | ||
| Rectum | 14 (14.0) | 5 (11.8) | 11 (14.9) | 8 (11.8) | ||
| PCI | 0.980 | 0.040 | ||||
| ≥20 | 12 (12.0) | 5 (11.8) | 5 (6.8) | 12 (17.6) | ||
| <20 | 88 (88.0) | 37 (88.1) | 69 (93.2) | 56 (82.4) | ||
| Histology | 0.630 | 0.950 | ||||
| Adenocarcinoma | 73 (73.0) | 29 (69.0) | 53 (71.6) | 49 (72.1) | ||
| Mucinous adenocarcinoma and signet ring cell carcinoma | 27 (27.0) | 13 (31.0) | 21 (28.4) | 19 (27.9) |
All values are presented as number of patients followed by percentage in the parentheses.
CRS = cytoreductive surgery, HIPEC = hyperthermic intraperitoneal chemotherapy, mutKRAS/wtKRAS = KRAS mutation/KRAS wild-type, mutBRAF/wtBRAF = BRAF mutation/BRAF wild-type.